Loading…
Ernexa Therapeutics Inc Is A Preclinical-Stage Synthetic Allogeneic Imsc Therapy Company Developing Medicines To Treat Various Forms Of Cancer And Other Diseases With High Unmet Medical Needs. Its Main Product Candidate, Erna-101, Capitalizes On The Intrinsic Tumor-Homing Ability Of Mscs (Mesenchymal Stem Cells) To Slip Through The Tumor'S Defenses And To Deliver Potent Pro-Inflammatory Factors Directly To The Tumor Microenvironment. The Firm'S Initial Focus Is To Develop Erna-101 In Platinum-Resistant Ovarian Cancer. Through Another Product Candidate, Erna-201, It Is Investigating Anti-Inflammatory Cytokine (Il-10) Secreting Imscs In Autoimmune Disorders Like Rheumatoid Arthritis. The Company Operates In A Single Reportable Segment, The Research And Development Of Cellular Therapies.